AMLX: חוב לטווח קצר של החברה Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals (AMLX) is revising its development portfolio, investing liquidity into the search for new molecules to combat rare genetic disorders. This price chart on the GURU.Markets platform reflects the asset's dynamics, with a metric of 0.00. The business currently lacks pricing power due to failures with its primary drug, which has triggered a large-scale structural reorganization. Meanwhile, the company is relying on partnerships with scientists and patient communities to develop neurodegeneration therapies.

This indicator captures total liabilities maturing within one year, determining the risk of liquidity loss. By analyzing short-term financial debts with a maturity of up to one year, an investor assesses the issuer's ability to service current loans. For Amylyx Pharmaceuticals (AMLX), this metric is critical due to the uncertainty of future revenues following the market recall of its drug. A high debt load amid unstable flows could trigger a cash crunch, rendering the asset high-risk.